ReNerve Posts Record Quarter as Sales Surge and Asia-Pacific Reach Expands
ReNerve reported record quarterly sales of approximately $584,000, up 176% on the previous quarter and 774% on the same quarter last year, with quarterly sales also exceeding its full-year result for 2025/26. The company secured access to up to $5 million in funding, received Indonesian marketing approval for its nerve cuff and completed its first cases in Hong Kong and Malaysia; it is also partnering with RMIT on a government-funded nerve regeneration research project. A separate notice says ReNerve will host an investor webinar on 2 November.
Closing price · 2026-10-26: $0.093 · +6.90%